People · Operator
Named in public records as an officer, director or promoter · active 2012–2019 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Melt Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $53.7M | $510.9M | 2019 |
| Harrow Health, Inc. | — | Pharmaceuticals | Series A | $29.2M | $226.5M | 2012 |
| Eton Pharmaceuticals, Inc. | — | Pharmaceuticals | Series B | $27.6M | $255.0M | 2017 |
Andrew Boll at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Boll on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Mark Baum | 3 | 4 |
| Mark L. Baum | 2 | 5 |
| Teresa F. Sparks | 1 | 30 |
| Richard Lindstrom | 1 | 13 |
| Paul Finnegan | 1 | 11 |
| Richard L Lindstrom | 1 | 8 |
| Paul V. Maier | 1 | 6 |
| Charles Casamento | 1 | 5 |
| Charles J Casamento | 1 | 5 |
| John Berdahl | 1 | 3 |
| Norbert G. Riedel | 1 | 3 |
| Larry Dillaha | 1 | 3 |
| Brad Osborne | 1 | 2 |
| Joachim Schupp | 1 | 2 |
| Robert Kammer | 1 | 2 |
| Sean Brynjelsen | 1 | 1 |
| Jeffrey Abrams | 1 | 1 |
| Balbir Brar | 1 | 1 |
| Robert J. Kammer | 1 | 1 |
| Andrew R. Boll | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.